When to Recheck GFR After Starting Jardiance
Recheck eGFR at 4 weeks after initiating Jardiance (empagliflozin) to assess the expected initial hemodynamic decline, then monitor according to baseline kidney function and clinical context.
Understanding the Expected eGFR Pattern
When you start Jardiance, an initial decline in eGFR is expected and normal—this is not kidney injury but rather a hemodynamic effect from reduced intraglomerular pressure 1. This is a key concept to understand:
Week 4: The FDA label notes that serum creatinine increases and eGFR decreases typically stabilize within weeks of starting therapy, with changes generally not exceeding -9.0 mL/min/1.73 m² by Week 4 1
The initial dip is protective: Research demonstrates that empagliflozin causes an average eGFR decline of approximately -7.5 to -7.9 mL/min within the first 4 weeks 2, 3, 4. This acute drop reverses after discontinuation, confirming it represents hemodynamic changes rather than structural kidney damage 1
Don't be alarmed by the dip: In the EMPEROR-Reduced trial, patients with early eGFR decreases (≤-11.4%) had no increased risk of adverse cardiovascular or renal outcomes compared to those whose eGFR increased 5. Clinicians should not be concerned with early eGFR changes post-initiation 5
Practical Monitoring Algorithm
Initial Check (Week 4)
- Recheck eGFR at 4 weeks to document the expected hemodynamic decline
- Expect a decline of 5-10 mL/min/1.73 m²
- Continue therapy unless eGFR drops >30% from baseline (which warrants investigation for other causes like volume depletion or acute kidney injury) 6
Subsequent Monitoring Based on Baseline eGFR
For eGFR ≥45 mL/min/1.73 m²:
- Recheck at 3-6 months, then annually if stable
- Standard CKD monitoring applies
For eGFR 30-44 mL/min/1.73 m² (Stage 3b CKD):
- Recheck at 3 months after the 4-week check
- Then every 3-6 months 7
- Continue empagliflozin 10 mg daily 7
For eGFR 20-29 mL/min/1.73 m² (Stage 4 CKD):
- More frequent monitoring: every 2-3 months
- Note: FDA labeling states "use not recommended" for empagliflozin with eGFR <45, but ADA/KDIGO guidelines support continuation for kidney and cardiovascular benefit until dialysis 7
If eGFR falls below 20 mL/min/1.73 m²:
- Continue the medication—evidence shows persistent benefit with no additional safety concerns 8
- Monitor every 1-2 months
- Continue until dialysis or transplantation 7, 8
Long-Term Benefit: The Slope Matters More Than the Dip
After the initial 4-week decline, empagliflozin actually slows long-term eGFR decline:
- During chronic maintenance (after Week 4), the annual eGFR slope with empagliflozin is +0.23 mL/min/1.73 m²/year versus -1.46 mL/min/1.73 m²/year with placebo 4
- This means you're preventing approximately 1.7 mL/min/1.73 m² of kidney function loss per year compared to not using the drug 4
Critical Pitfalls to Avoid
Don't stop the drug due to the initial eGFR dip: This is the expected mechanism of action, not toxicity 5, 4
Do assess volume status at Week 4: The initial decline can be larger if the patient is volume depleted. Correct volume depletion before or during initiation 7, 1
Watch for >30% eGFR decline within 3 months: This warrants specialist referral to rule out other causes (acute tubular necrosis, obstruction, etc.) 6
Don't discontinue when eGFR falls below package insert thresholds: Guidelines explicitly recommend continuation for cardiorenal benefit even when eGFR drops below FDA-labeled thresholds 7, 6
Monitor for acute illness: Pause SGLT2 inhibitors during periods of acute illness or stressors to reduce ketoacidosis risk 7
Special Populations
Patients with hyperfiltration (eGFR >126.8 mL/min/1.73 m²):
- Expect more pronounced initial decline (-11.67 mL/min/1.73 m²) 9
- This is actually beneficial—15% shifted from hyperfiltration to normal range at 26 weeks 9
- Recheck at 4 weeks and 6 months
Patients hospitalized for acute heart failure: